Clinical Trial Update: Rituximab to Treat Neuropathy With Anti-MAG Antibodies [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating rituximab for anti-MAG antibody-associated polyneuropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polyneuropathy

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Polyneuropathies | Phase 2 | Status: COMPLETED